Monoclonal Antibodies Blocking S. Aureus Coagulase-Prothrombin Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Staphylococcus aureus infections, particularly acute infective endocarditis, are challenging due to high mortality rates, antibiotic resistance, and the inability of immune defenses to reach heart valves effectively, leading to complications like vegetations that protect bacteria from clearance.
Innovation Solution
Development of monoclonal antibodies that target staphylocoagulase (SC) and von Willebrand factor-binding protein (vWbp) to inhibit their interaction with prothrombin, preventing fibrin formation and bacterial protection, using specific antibodies alone or in combination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibiotic therapy is used to treat S. aureus infections, then bacterial growth may be inhibited, but antibiotic resistance develops and treatment effectiveness decreases
Solution Approach 1:
The patent extracts and targets the specific virulence mechanism (coagulase-prothrombin interaction) rather than using broad-spectrum antibiotics. By isolating and blocking the specific pathogenic pathway with monoclonal antibodies, the treatment achieves effectiveness without selecting for general antibiotic resistance.
Solution Approach 2:
The patent introduces monoclonal antibodies as intermediary substances that block the interaction between staphylocoagulase and prothrombin. These antibodies act as mediators that prevent the formation of protective fibrin clots without directly killing bacteria, thereby avoiding resistance development.
2Adaptability or versatility
If immune defenses are relied upon to clear S. aureus from heart valves, then no additional drugs are needed, but the blunted immune response at heart valves prevents effective clearance
Solution Approach 1:
The patent enhances the body's own immune mechanisms by blocking the bacterial virulence factor that suppresses immune function. By preventing coagulase-mediated immune evasion and fibrin formation, the host immune system can effectively clear the infection without requiring additional pharmacological immunomodulation.
3Quantity of substance
If drugs are delivered via bloodstream to treat heart valve infections, then systemic coverage is achieved, but drugs have difficulty reaching infected valves due to lack of blood supply
Solution Approach 1:
The patent uses monoclonal antibodies as intermediaries that can effectively reach the infection site by binding to bacterial surface antigens. The antibodies traverse the limited blood supply and accumulate at the infected valve through antigen-antibody interactions, overcoming the delivery barrier.
4Object-affected harmful factors
If broad-spectrum antibiotic therapy is used to prevent resistance, then all bacterial strains are targeted, but side effects and loss of beneficial bacteria occur
Solution Approach 1:
The patent applies local quality by targeting the specific coagulase-prothrombin interaction pathway with high-affinity monoclonal antibodies. This localized targeting of the virulence mechanism eliminates bacteria through immune modulation without the broad-spectrum effects that cause collateral damage to beneficial microbiota.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively prevent fibrin formation and improve survival rates in animal models by targeting S. aureus infections locally, avoiding systemic side effects associated with traditional treatments.
Implementation Method 1
The monoclonal antibodies and fragments therefrom disclosed herein are able to bind to and interfere with, modulate, and/or inhibit the binding interactions between at least staphylocoagulase and/or von Willebrand binding protein and prothrombin
Data Source
AI summary
We provide new monoclonal antibody inhibitors of coagulases, staphylocoagulase (“SC”) and von Willebrand factor-binding protein (“vWbp”) for treatment of S. aureus. The monoclonal antibodies are useful in targeting the SC N-terminus of SC and vWbp (respectively) and inhibiting prothrombin activation. The monoclonal antibodies are able to bind to and interfere with, modulate, and/or inhibit the binding interactions between the coagulase protein and its ligan protein prothrombin the activation of prothrombin.